Intercept Pharmaceuticals — J.P. Morgan Healthcare Conference 2023
23 slides from Intercept Pharmaceuticals's conference presentation, Jan 11, 2023

Slide 1: Intercept Pharmaceuticals J.P. Morgan Healthcare Conference
Intercept Pharmaceuticals J.P. Morgan Healthcare Conference Jerry Durso, President and CEO January 12, 2023

Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation is intended for investor purposes only and is not intended for promotional purposes. 2 Cautionary Note Regarding Forward - Looking Statements ("FLS") This document contains FLS, including regarding : our finances, financial guidance, and financial results, including expectations re

Slide 3: Our mission is to build a healthier tomorrow for people with progressive non-viral liver diseases
Our mission is to build a healthier tomorrow for people with progressive non - viral liver diseases

Slide 4: Intercept Today: Established Expertise in Liver Disease
Intercept Today: Established Expertise in Liver Disease 4 This presentation is intended for investor purposes only and is not intended for promotional purposes. Sustainable and growing PBC business with Ocaliva Fully integrated organization with ~350 employees focused exclusively in liver disease St

Slide 5: Strong Financial Foundation for Future Growth and Success
Strong Financial Foundation for Future Growth and Success 5 This presentation is intended for investor purposes only and is not intended for promotional purposes. 2022 Actions and Select Financial Results Impact in 2023 • $450M sale of rights to Ocaliva in PBC outside the U.S. • $389M 2026 convertib

Slide 6: Sustainable and Growing PBC Business with Ocaliva
Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities Jennie, Living with PBC Sustainable and Growing PBC Business with Ocaliva

Slide 7: Ocaliva in PBC – A Strong Foundational Business
Ocaliva is approved for the treatment of PBC* in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA Ocaliva in PBC – A Strong Foundational Business 7 This presentation is intended for investor purposes only

Slide 8: Our Ocaliva Business Shows Strong Growth in 2022
Our Ocaliva Business Shows Strong Growth in 2022 (Unaudited) This presentation is intended for investor purposes only and is not intended for promotional purposes. 0 50 100 150 200 250 300 2016 2017 2018 2019 2020 2021 2022 Millions (USD) U.S. Ocaliva Net Sales ~10% growth 8 ~$285M NS0 JD1 KP2 NS3

Slide 9: Pathway for Long-Term Ocaliva Growth
>60% 85% ~90% 89% Pathway for Long - Term Ocaliva Growth This presentation is intended for investor purposes only and is not intended for promotional purposes. Demonstrating a need to go beyond ALP management in fully addressing PBC treatment 9% increase in first - time writers (Rx) in 2022 vs. 2021

Slide 10: Data Demonstrates Long-Term Improved Clinical Outcomes in Patients Taking OCA for PBC
A 70% lower risk of death or liver transplant compared to control patients was demonstrated in a key publication in Gastroenterology 1 Data Demonstrates Long - Term Improved Clinical Outcomes in Patients Taking OCA for PBC 10 This presentation is intended for investor purposes only and is not intend

Slide 11: Fixed-Dose Combination of OCA+Bezafibrate May Establish New Best-in-Class Clinical Benefits
Fixed - Dose Combination of OCA+Bezafibrate May Establish New Best - in - Class Clinical Benefits 11 This presentation is intended for investor purposes only and is not intended for promotional purposes. Exploring the potential for improved efficacy and tolerability with a fixed - dose combination o

Slide 12: Progressing OCA for Pre-Cirrhotic Liver Fibrosis due to NASH
Sustainable and Growing PBC Business with Ocaliva Terri, Living with Advanced Fibrosis due to NASH Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities

Slide 13: OCA: Unique Opportunity To Help NASH Patients With Pre-Cirrhotic Fibrosis
OCA: Unique Opportunity To Help NASH Patients With Pre - Cirrhotic Fibrosis due to NASH 13 This presentation is intended for investor purposes only and is not intended for promotional purposes. NDA re - submitted in December 2022; anticipating a PDUFA target review time of six months OCA is an antif

Slide 14: Reaching Patients with OCA at a Pivotal Point in NASH Disease Progression
Reaching Patients with OCA at a Pivotal Point in NASH Disease Progression 14 This presentation is intended for investor purposes only and is not intended for promotional purposes. • Predominantly managed in primary care • Focus on screening for fibrosis in at - risk populations • Treatment goals are

Slide 15: REGENERATE: Largest and Longest-Running Pivotal Phase 3 Study in Fibrosis Due to NASH
REGENERATE: The First, Largest and Longest - Running Pivotal Phase 3 Study in Patients With Fibrosis Due to NASH Achieved its Primary Endpoint in Two Analyses 15 This presentation is intended for investor purposes only and is not intended for promotional purposes. PATIENT POPULATION 2,480 patients w

Slide 16: OCA Demonstrated Strong Antifibrotic Effect and Manageable Safety Profile
OCA Demonstrated Strong Antifibrotic Effect and Monitorable and Manageable Safety Profile 16 This presentation is intended for investor purposes only and is not intended for promotional purposes. Robust safety assessment of 2,477 patients, including 1,000 on study drug for four years demonstrated a

Slide 17: Intercept Is Poised To Deliver OCA in NASH Upon Approval
Intercept Is Poised To Deliver OCA in NASH Upon Approval 17 This presentation is intended for investor purposes only and is not intended for promotional purposes. of highest potential Heps/GIs are within our existing PBC customer base Established U.S. field presence with broad geographic footprint •

Slide 18: Advancing Internal Pipeline, 2023 Priorities
Sustainable and Growing PBC Business with Ocaliva Progressing OCA for Pre - Cirrhotic Liver Fibrosis due to NASH Advancing Internal Pipeline, 2023 Priorities

Slide 19: Clinical Development Programs
Clinical Development Programs 19 This presentation is intended for investor purposes only and is not intended for promotional purposes. *Currently used for investigational purposes only. Has not been approved by the FDA or any other worldwide regulatory agency. Sa fety and efficacy have not been est

Slide 20: Advancing INT-787 in Lead Indication: Severe Alcohol-Associated Hepatitis
Advancing INT - 787 in Lead Indication: Severe Alcohol - Associated Hepatitis 20 This presentation is intended for investor purposes only and is not intended for promotional purposes. Alcohol - related liver disease is currently the leading indication for liver transplant listing in the U.S., with a

Slide 21: 2023 Strategic Priorities: Building on Strong Foundation in Liver Disease
2023 Strategic Priorities: Building on Strong Foundation in Liver Disease This presentation is intended for investor purposes only and is not intended for promotional purposes. 21 Gain FDA approval for OCA in NASH Advance internal pipeline in liver diseases with high unmet need Continue to maintain

Slide 22: Appendix
Appendix Intercept |J

Slide 23: Q4 and FY 2022 Financial Highlights / Reconciliation of Non-GAAP Adjusted Net Sales
Q4 and FY 2022 Financial Highlights / Reconciliation of Non - GAAP Adjusted Net Sales To Total Revenue (Unaudited) 23 This presentation is intended for investor purposes only and is not intended for promotional purposes. Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022
Source: SEC EDGAR · 8-K filed Jan 11, 2023

